BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 109 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $160 | -41.4% | 22,609 | -41.8% | 0.02% | -52.9% |
Q2 2023 | $273 | -99.9% | 38,825 | +42.4% | 0.03% | +3.0% |
Q2 2022 | $288,000 | -1.7% | 27,257 | +51.3% | 0.03% | -5.7% |
Q1 2022 | $293,000 | -23.9% | 18,017 | -32.7% | 0.04% | -23.9% |
Q3 2021 | $385,000 | +296.9% | 26,774 | +32.0% | 0.05% | +206.7% |
Q2 2020 | $97,000 | -2.0% | 20,284 | -58.9% | 0.02% | -21.1% |
Q1 2020 | $99,000 | -18.9% | 49,335 | +207.7% | 0.02% | +11.8% |
Q3 2018 | $122,000 | -15.3% | 16,036 | -38.0% | 0.02% | -37.0% |
Q2 2017 | $144,000 | -57.3% | 25,885 | -35.6% | 0.03% | -65.8% |
Q1 2017 | $337,000 | +524.1% | 40,190 | +110.3% | 0.08% | +426.7% |
Q1 2016 | $54,000 | -74.9% | 19,107 | +32.7% | 0.02% | -80.0% |
Q2 2015 | $215,000 | – | 14,397 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |